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The clinical course of idiopathic pulmonary fibrosis (IPF) is difficult to predict, partly owing to its 
heterogeneity. Composite physiologic index (CPI) and gender-age-physiology (GAP) models are easy-
to-use predictors of IPF progression. This study aimed to compare the predictive values of these two 
models. From 2003 to 2007, the Korean Interstitial Lung Disease (ILD) Study Group surveyed ILD 
patients using the 2002 ATS/ERS criteria. A total of 832 patients with IPF were enrolled in this study. 
CPI was calculated as follows: 91.0 − (0.65 × %DLCO) − [0.53 × %FVC + [0.34 × %FEV1. GAP stage was 
calculated based on gender (0–1 points), age (0–2 points), and two physiologic lung function parameters 
(0–5 points). The two models had similar significant predictive values for patients with IPF (p < 0.001). 
The area under the curve (AUC) was higher for CPI than GAP for prediction of 1-, 2-, and 3-year 
mortality in this study. The AUC was higher for surgically diagnosed IPF patients than for clinically 
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diagnosed patients. However, neither CPI nor GAP yielded good predictions of outcomes; the AUC was 
approximately 0.61~0.65. Although both CPI and GAP stage are significantly useful predictors for IPF, 
they have limited capability to accurately predict outcomes.
Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown origin that is chronic, progressive, 
and eventually fatal. IPF mainly affects older adults, especially those in their sixth and seventh decades. Despite 
promising results with novel drugs such as pirfenidone and nintedanib, the mortality of patients with IPF remains 
high; median survival time is 2.5–3.5 years1–3. Furthermore, IPF disease progression is highly variable; while some 
IPF patients experience a reduction of symptoms over time, others are stable, experience slow worsening of res-
piratory symptoms or pulmonary function, or have acute exacerbation of symptoms, ultimately leading to death1. 
Therefore, clinicians usually face challenges in predicting the clinical course in newly diagnosed IPF patients. 
Precise prediction of clinical course is important for developing treatment plans and providing clinicians with 
accurate information that must be communicated to patients and medical teams4.
Previous studies used clinical factors (age, gender, smoking status, finger clubbing, dyspnea, 6-minute walk-
ing distance, and hospitalization), pulmonary function tests (PFTs), change in PFT, high-resolution computed 
tomography (HRCT) findings or scores, pulmonary hypertension, molecular biomarkers (metalloproteinase-7 
and C-reactive protein [CRP]), and pathologic finding as variables in predictive models5–11. However, most of 
these predictive models are too complex to use and have not been validated externally.
In 2003, Wells et al.12 reported on their composite physiologic index (CPI), which was developed as a tool to 
reflect the morphologic extent of pulmonary fibrosis in IPF on computed tomography (CT) (r = 0.71, r2 = 0.51, 
P < 0.0005); it is calculated easily based on lung function parameters. CPI was a more powerful prognos-
tic marker for mortality than either lung function or alveolar-arterial O2 gradient in surgically diagnosed IPF 
patients (P < 0.0005).
However, gender-age-physiology (GAP) stage, which based on the Fine-Gray competing risk models by Ley et al.13 
in 2012, uses gender, age, and two pulmonary function results (percent predicted forced vital capacity [FVC] 
and percent predicted diffusing capacity of the lung for carbon monoxide [DLCO]). Ley et al. analyzed a relatively 
large cohort; they obtained a C-index of 69.3 in the derivation cohort (n = 228) and 68.7 in the validation cohort 
(n = 330).
The aim of this study was to validate and compare the predictive values of CPI and GAP stage models in the 
Korean population.
Methods
Patient selection. In this retrospective study, patients with newly diagnosed interstitial lung disease (ILD) 
were enrolled by the Korean Interstitial Lung Disease Research Group from January 1, 2003, through December 
31, 200714. The cut-off date was December 31, 2009. The diagnosis was performed by pulmonologists, radiolo-
gists, and pathologists at each hospital, and diagnosis was reconfirmed by the Scientific Committee at the Korean 
Academy of Tuberculosis and Respiratory Diseases. Fifty-four hospitals registered a total of 2,186 ILD patients. 
Patients with a condition other than IPF (n = 501) and patients with incomplete data (n = 423) were excluded 
from this study. We diagnosed IPF according to the previous international consensus statement by the American 
Thoracic Society (ATS), European Respiratory Society (ERS), and the American College of Chest Physicians15,16. 
Of 1,262 IPF patients, 430 patients lost to follow-up were also excluded from this study. As a result, a total of 832 
patients with IPF were included in this study. The clinical data (age, sex, smoking, respiratory symptoms, diagnos-
tic method, and mortality), radiologic findings (HRCT), laboratory data (arterial blood gas analysis, CRP, antinu-
clear antibody [ANA], and rheumatoid factor [RF]), and physiological data (PFT) were investigated. These data 
were saved in a web-based registry system (www.ild.or.kr). The mean follow-up period was 22.5 ± 16.3 months.
Predictive model. CPI was calculated according to Wells et al.12: CPI parameters as follows: 91.0 – 
(0.65 × DLCO percentage of the predicted value [% pred]) − (0.53 × FVC % pred) + (0.34 × forced expiratory 
volume [FEV1] % pred). Mura et al.11 showed that a CPI > 41.0 was significantly associated with 3-year survival 
in a prospective cohort (hazard ratio [HR] = 5.36, P = 0.0071), as well as in a retrospective cohort (HR = 4.20, 
P = 0.042). Based on their study, our patients were divided into two groups according to the calculated CPI value 
(≤41.0 and >41.0), and their characteristics were examined. GAP score was calculated according to Ley et al.13: 
gender (0–1 points), age (0–2 points), %FVC (0–2 points), and %DLCO (0–3 points). However, the category “can-
not perform DLCO (3 points)” was not considered in the present study because of the retrospective nature of the 
study. GAP stage was determined based on the total GAP score: stage I (0–3 points), stage II (4–5 points), and 
stage III (6–8 points).
The primary objective of this study was to compare the predictive ability of CPI and GAP stage models for 
1-year, 2-year, and 3-year mortality.
Statistical analysis. Continuous variables were compared by t-test or analysis of variance (ANOVA) accord-
ing to the number of groups, and these variables were presented as means ± standard deviation. Comparisons 
between GAP stages were performed with ANOVA, and post hoc analyses were conducted using Bonferroni’s 
correction. Categorical variables were analyzed by Pearson’s chi-square test, and these categorical variables were 
presented as frequency (n) and percentage (%). The predictive receiver operating characteristic (ROC) curves of 
1-year, 2-year, and 3-year mortality were compared between CPI and GAP models. All statistics were analyzed 
with SPSS™ Version 22.0 (SPSS, Chicago, IL, USA). We considered an adjusted p-value less than 0.05 as statisti-
cally significant.
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Ethics statement. The Institutional Review Board (IRB) of Seoul National University Bundang Hospital 
approved this study protocol (IRB approval number: B-1709/420-102). Informed patient consent was waived 
due to the retrospective nature of our study. All methods were performed in accordance with the Declaration of 
Helsinki.
Results
Demographic characteristics. The baseline characteristics of the study population are presented in 
Table 1. The mean age of study population was 66.4 ± 9.3 years. Male gender was more prevalent than female 
gender (72.0% versus 23.0%). The most common respiratory symptom was dyspnea (68.0%), followed by cough 
(58.3%). However, 40 (4.8%) patients were asymptomatic. Mean smoking duration was 35.6 ± 12.7 years and 
mean smoking amount was 34.8 ± 20.0 pack-years. 73 patients (8.8%) had decreased lung function consistent 
with COPD (FEV1/FVC < 0.7 and age ≥40 years). A total of 380 (45.7%) patients were diagnosed by the surgical 
method, and 452 (54.3%) patients were diagnosed on the basis of clinical and radiographic criteria. Mean CPI 
was 38.6 ± 15.5; 460 (55.3%) patients had a CPI ≤ 41, and 372 (44.7%) patients had a CPI > 41 (Table 2). One-year 
mortality was 17.3%, 2-year mortality was 24.3%, and 3-year mortality was 29.7%. According to GAP, there were 
536 (64.4%) stage I patients, 268 (32.2%) stage II patients, and 28 (3.4%) stage III patients.
Tables 2 and 3 show the clinical, radiologic, and physiologic characteristics according to CPI and GAP stage. 
The elevated CPI group (CPI > 41) was significantly associated with aging, low lung function, and low arterial 
oxygen tension (PaO2) (similar to advanced GAP stage). However, male sex was significantly predominant in the 
group with CPI ≤ 41 than in the group with CPI > 41. Radiologic findings were not significantly different between 
the two groups (CPI ≤ 41 and CPI > 41).
Advanced GAP stage was significantly associated with aging, reduced lung function, low PaO2, and higher 
mortality rate. CPI were significantly increased in patients with advanced GAP stage (P < 0.001). However, 
in radiologic findings, only the percentage of honeycombing was significantly different among GAP stages 
(P = 0.043).
Survival according to predictive models. CPI and GAP stage significantly predicted disease progression 
according to the Cox proportional hazard model (Table 4). The HR increased with increased CPI score (P < 0.001; 
HR, 1.025; 95% confidence interval [CI], 1.017–1.034), GAP score (P < 0.001; HR, 1.332; 95% CI, 1.222–1.451), 
and with advanced GAP stage. The predictive value of CPI and GAP stage at 1-year, 2-year, and 3-year mortality 
was assessed by ROC curve analysis. Each model showed significant predictive capacity at all time points. ROC 
curves for all patients with IPF are shown in Fig. 1. The area under the curve (AUC) for 1-year mortality was 
Variable
Age at diagnosis, yr 66.4 ± 9.3
Gender (F:M) 233 (28.0): 599 (72.0)
Duration of symptoms at diagnosis (month) 11.2 ± 20.9
   Dyspnea of exertion(%) 566 (68.0)
   Cough (%) 485 (58.3)
   Sputum (%) 262 (31.5)
   Hemoptysis (% 18 (2.2)
   Chest pain (% 50 (6.0)





Smoking duration (year) 35.6 ± 12.7







CPI 38.6 ± 15.5
GAP stage (I/II/III) 536 (64.4)/268 (32.2)/28 (3.4)
Table 1. Baseline characteristics of IPF patients (n = 832). Note: Values in parentheses are percentages. 
*Smoking status were available for 769 patients. CPI = 91.0 − (0.65 * DLCO [%]) − (0.53 * FVC [%]) + (0.34 
* FEV1 [%]). ANA, antinuclear antibody; CPI, composite physiologic score; CRP, C-reactive protein; DLCO, 
diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume; FVC, forced vital capacity; 
GAP, (G, 0–1 point), age (A, 0–2 points), and 2 lung physiology variables (P, FVC and DLCO); RF, rheumatoid 
factor.
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0.619 for GAP stage and 0.647 for CPI. The AUC for 2-year mortality was 0.625 for GAP stage and 0.647 for CPI. 
The AUC for 3-year mortality decreased; it was 0.610 for GAP stage and 0.639 for CPI. CPI predicted survival 
more accurately than did GAP stage for all time points modelled, but the difference in AUC was not statistically 
CPI ≤ 41 (n = 460) CPI > 41 (n = 372) P-value
Age 65.6 ± 9.0 67.3 ± 9.5 0.007
Gender (F:M) 116 (25.2)/344 (74.8) 117 (31.5)/255 (68.5) 0.046
Pulmonary function test
   FVC (%) 84.1 ± 17.3 69.2 ± 16.2 <0.001
   FEV1 (%) 92.9 ± 18.6 81.7 ± 19.4 <0.001
   TLC (%) 89.8 ± 18.9 74.5 ± 16.8 <0.001
   DLCO (%) 77.0 ± 17.6 46.7 ± 11.8 <0.001
Resting PaO2 mm Hg 86.5 ± 22.5 78.8 ± 20.0 <0.001
Resting PaCO2 mm Hg 38.4 ± 7.8 36.2 ± 6.9 0.001
Radiologic finding
   Reticular pattern 298 (68.0) 231 (68.5) 0.880
   Honeycombing change 323 (74.9) 277 (78.7) 0.217
   Ground glass opacities 279 (64.3) 206 (63.4) 0.798
   Nodular lesions 94 (23.2) 70 (22.8) 0.898
GAP stage (I/II/III) 388/72/0 148/196/28 <0.001
Death (%) 112 (24.3) 161 (43.3) <0.001
Table 2. Clinical, radiographic, and physiologic characteristics according to composite physiologic index (CPI). 
CPI, composite physiologic score; CRP, C-reactive protein; DLCO, diffusing capacity of the lung for carbon 
monoxide; FEV1, forced expiratory volume; FVC, forced vital capacity; GAP, (G, 0–1 point), age (A, 0–2 points), 
and 2 lung physiology variables (P, FVC and DLCO); PaO2, arterial oxygen tension; PaCO2, arterial carbon 
dioxide tension; TLC, total lung capacity.
GAP stage I (n = 536) GAP stage II (n = 268) GAP stage III (n = 28) P-value
Age 63.6 ± 9.1 71.4 ± 7.4 71.8 ± 4.5 <0.001
Gender (F:M) 194 (36.2): 342 (63.8) 38 (14.2): 230 (85.8) 1 (3.6): 27 (96.4) <0.001
Pulmonary function test
   FVC (%) 83.0 ± 17.2 68.8 ± 16.0 55.9 ± 12.6 <0.001
   FEV1 (%) 92.6 ± 19.1 81.0 ± 17.8 64.4 ± 13.6 <0.001
   TLC (%) 86.6 ± 19.2 77.9 ± 18.1 69.9 ± 25.8 <0.001
   DLCO (%) 69.8 ± 18.9 54.3 ± 20.6 30.2 ± 11.4 <0.001
Resting PaO2 mm Hg 86.5 ± 21.7 77.3 ± 20.9 71.2 ± 12.6 <0.001
Resting PaCO2 mm Hg 38.3 ± 7.7 35.8 ± 7.0 36.1 ± 6.9 0.002
Radiologic finding
   Reticular pattern 353 (69.2) 162 (67.2) 14 (58.3) 0.490
   Honeycombing change 372 (73.8) 206 (81.7) 22 (81.5) 0.043
   Ground glass opacities 331 (65.3) 136 (59.1) 18 (81.8) 0.056
   Nodular lesions 116 (24.1) 43 (20.5) 5 (23.8) 0.577
CPI 33.2 ± 13.5 46.8 ± 13.4 63.7 ± 7.4 <0.001
Death (%) 139 (25.9) 118 (44.0) 16 (57.1) <0.001
Table 3. Clinical, radiographic, and physiologic characteristics according to GAP stage. ‡The following post 
hoc comparisons were significant at the P = 0.05 level; all other comparisons were non-significant: GAP stage I 
versus GAP stage II, and GAP stage III (age); GAP stage I versus GAP stage II and GAP stage III, and GAP stage 
II versus GAP stage III (FVC [%]); GAP stage I versus GAP stage II and GAP stage III, and GAP stage II versus 
GAP stage III (FEV1 [%]); GAP stage I versus GAP stage II and GAP stage III (TLC [%]); GAP stage I versus 
GAP stage II and GAP stage III, and GAP stage II versus GAP stage III (DLCO [%]); GAP stage I versus GAP 
stage II, and GAP stage III (PaO2); GAP stage I versus GAP stage II (PaCO2); GAP stage I versus GAP stage II 
and GAP stage III, and GAP stage II versus GAP stage III (CPI). CPI = 91.0 − (0.65 * DLCO [%]) − (0.53 * FVC 
[%]) + (0.34 * FEV1 [%]). CPI, composite physiologic score; CRP, C-reactive protein; FEV1 = forced expiratory 
volume; FVC = forced vital capacity; TLC = total lung capacity; DLCO = diffusing capacity of the lung for 
carbon monoxide; GAP, (G, 0–1 point), age (A, 0–2 points), and 2 lung physiology variables (P, FVC and DLCO); 
PaO2 = arterial oxygen tension; PaCO2 = arterial carbon dioxide tension.
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significant (Table S1 [Supplementary Information]). Well et al. reported that CPI had the greatest prognostic 
significance compared with lung function results or PaO2 in biopsy-proven IPF. Therefore, we investigated the 
GAP stage and CPI in surgically diagnosed IPF patients (Fig. S1 and Table S1 [Supplementary Information]). In 
surgically diagnosed IPF patients, the AUC for 1-year mortality was 0.622 for GAP stage and 0.673 for CPI. The 
AUC for 2-year mortality was 0.624, and 0.674, respectively. The AUC for 3-year mortality was 0.602, and 0.667, 
respectively. Generally, CPI was a more accurate predictor of mortality than GAP stage. In clinically diagnosed 
IPF patients, the two predictive models showed statistically significant AUC values, but no significant differences 
were found between them (Fig. S2 [Supplementary Information]). The predictive value for outcome with AUC 
was under 0.62 in clinically diagnosed IPF patients, which was lower than the value in surgically diagnosed IPF 
patients.
Discussion
CPI and GAP stage are easy to use and can be calculated in-office during the initial visit and thereafter during 
follow-up visits. CPI can be calculated from PFT results, and the GAP stage calculation requires only age and gen-
der in addition to PFT results12,13. In this retrospective study, we compared the predictive value of CPI and GAP 
stages. Both were effective for predicting mortality. However, both models had a limited capability to provide 
accurate prognoses for IPF patients.
As mentioned previously, predictive models of IPF prognosis rely on numerous clinical factors, physiologic 
parameters, radiologic features, biomarkers, and pathologic findings5–11,17,18. Most models developed to date are 
complex. In this study, we demonstrated that two simple-to-use models (GAP stage and CPI) have important 
predictive values. CPI was developed in a British study and has the advantage of relying on PFT data to predict 
IPF prognosis. Additionally, CPI was developed by considering the severity of emphysema, which could lead to 
overestimation of lung function19. However, CPI also has disadvantages: it does not consider clinical data such as 
age, gender, smoking history, presence of desaturation, or 6-minute walk distance. Furthermore, the value of CPI 
as a prognostic model is not well-studied. In the original publication, this issue had been determined only in 32 
histologically proven subjects with the usual interstitial pneumonia pattern, leading to the hypothesis that CPI 
may be useful as a prognostic marker12. In this study, we tested CPI as a predictive model for 1-, 2-, and 3-year 
mortality with a relatively large cohort (n = 832); CPI was effective for prediction of the outcomes of IPF patients 
(P < 0.001, Table 4), and the AUC was approximately 0.61–0.65 in all patients. Additionally, CPI was more accu-
rate than GAP stage, regardless of time of year or diagnostic method.
GAP staging, which was developed in a study in the United States and Italy, uses the clinical data of gender 
and age, and two sets of physiological data. However, it does not consider HRCT findings. Coexistent emphysema 
can be a confounding factor due to increasing %FVC, which could cause clinicians to render a good prognosis 
with a low GAP score20. In our study, although GAP stage showed a lower AUC value than CPI in predicting 1-, 
2-, and 3- year mortality, it exhibited significance in the prediction of mortality (Table 4). Similarly, Sharp et al.21  
reported that the AUC is lower in the GAP staging system than the CPI at both 12 months and 24 months. 
Additionally, age showed higher AUC than the GAP staging system at 12 months in their study. These findings 
could mean that gender is not a strong predictor of mortality. Furthermore, the pathophysiology of IPF is so 
complex that even multi-dimensional approaches might fail to predict the prognosis with sufficient accuracy22. 
Additional assessment of changes in functional lung capacity over time or biomarkers could be helpful in improv-
ing predictability23.
In our study, advanced GAP stage was understandably significantly associated with aging, male gender, and 
poor lung function. However, patients with elevated CPI (CPI > 41) showed significantly low predominance of 
male gender compared with patients with low CPI (CPI ≤ 41). This could mean that gender has a lesser effect 
on survival compared with age, HRCT, or PFT. Some studies have shown that gender affects survival, but others 
have reported no association between the two factors6,10,24–26. King et al.6 showed there was no significant gender 
difference on median survival using Kaplan–Meier analysis (P = 0.15; men, 30.0 months; CI: 19.1–44.3; women, 
39.3 months; CI: 19.1–44.3). On the contrary, Flaherty et al.27 showed that female gender was protective in IIP, 
and when surgically diagnosed IPF patients were added to the analysis, female gender showed a significantly low 
HR. Douglas et al.28 also reported that male gender was significantly associated with a worse outcome.
CPI was more precise in surgically proven IPF patients in our study (Figs S1, S2). Generally, physicians are 





hazard rate 95% CI P-value
CPI 832 1.025 1.017–1.034 <0.001
GAP score 832 1.332 1.222–1.451 <0.001
GAP stage <0.001
  Stage I 536
  Stage II 268 1.954 1.528–2.498 <0.001
  Stage III 28 2.518 1.500–4.225 <0.001
Table 4. Univariate analysis of survival in idiopathic pulmonary fibrosis using Cox proportional hazard model 
(3-year survival). CPI = 91.0 − (0.65 * DLCO [%]) − (0.53 * FVC [%]) + (0.34 * FEV1 [%]). CPI, composite 
physiologic score; FEV1 = forced expiratory volume; FVC = forced vital capacity; GAP, (G, 0–1 point), age (A, 
0–2 points), and 2 lung physiology variables (P, FVC and DLCO).
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patients showed a significantly lower GAP index and lower CPI level than clinically diagnosed IPF patients 
(Supplementary Table 1). These results may mean that the predictive capabilities of CPI and the GAP stage sys-
tem are more accurate in early IPF patients than in advanced IPF patients, and these models are not very reliable 
for longitudinal assessment. Recently, another study demonstrated that previous multi-dimensional indices for 
IPF were not more powerful as prognostic markers than clinical or physiologic parameters; DLCO is the more 
powerful prognostic marker on longitudinal follow-up than CPI or GAP stage21. These could mean that although 
these two models were created taking into consideration age, gender, lung function, and CT findings, these data 
were not sufficient to predict the outcome due to the heterogeneity of IPF. Further risk assessments (e.g., 6-minute 
walking test, oxygen demand, hospitalization due to respiratory problem, pulmonary hypertension, acute exac-
erbation, or lung cancer), should be considered for a more precise prediction of prognosis in IPF, especially for 
longitudinal follow-up.
Although GAP stage and CPI models showed significant capability in prediction and association with relative 
risk (Table 4) on mortality, the AUC values of the CPI and GAP stage were low in this study, especially those 
for 3-year mortality in GAP stage. This may be due to ethnic differences, complexity of the pathophysiology of 
IPF itself, and uneven distribution of population in the GAP stage (low numbers in GAP stage III). Kim et al.26 
demonstrated that the GAP model failed to predict 3-year mortality with Korean patients. Additionally, 430 
(34.1%) patients were lost to follow-up and excluded in this study. This sizeable patient set could have resulted in 
selection bias, and may have caused a decrease in the predictive capabilities of the two models. Furthermore, this 
study may have included some patients with combined pulmonary fibrosis and emphysema (CPFE). Although the 
prognosis between IPF and CPFE is still unclear, patients with CPFE could affect the GAP model30–32.
This study had some limitations. First, our patients were diagnosed based on the ATS/ERS criteria published 
in 200215,16. Therefore, IPF patients, who were diagnosed based on 2011 ATS/ERS/JRS/ALAT guidelines could 
have a different prognosis1. However, GAP stage and CPI were also first tested in patients who were diagnosed 
using the 2002 guidelines. Second, we could not correlate HRCT finding with CPI score. Although CPI was also 
elevated in patients with advanced GAP stage in a previous study from Japan, CPI has not yet been validated in 
Asian patients33. Third, our study is retrospective in nature, so we excluded patients who did not undergo DLCO 
testing, many of whom may have been included in the “cannot perform DLCO” category in the GAP stage model. 
As a result, the GAP stage III group was small compared with the others, which could result in selection bias.
In conclusion, both GAP stage and CPI showed significant capabilities to predict mortality, and CPI was 
more accurate than GAP stage in predicting mortality at 1, 2, and 3 years. However, the complexity of IPF and 
the inconsistencies in physiologic and clinical parameters limit the capability of both models to provide accurate 
prognoses for IPF patients. Further large-scale prospective studies are needed to investigate a more accurate 
predictive model.
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